Abstract：
Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been applied for treating axial spondyloarthritis (axSpA). However, there is a glaring absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were used to analyze and visualize the quantity and citations of publications, as well as to identify \"research hotspots\" and trends in this field. BibExcel version 1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA were included in this bibliometric analysis. Overall, the number of publications has been increasing steadily annually. The USA (23.21%, 591 publications) ranked first with the largest output of papers, followed by Germany, and the Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher (119 articles). Annals of the Rheumatic Diseases published the most documents (6.76%, 172 publications) in this field. The predominant hotspots have been \"tuberculosis,\" \"IL-17,\" and \"quality of life\" in the field until 2020. Since 2015, \"biosimilar pharmaceuticals\" has retained the popularity. Current research hotspots are \"spinal radiographic progression,\" Janus kinase (JAK) inhibitors, and adverse events (AEs). Machine learning has become popular gradually. Globally, there has been a steady increase in the number of studies on bDMARDs use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar pharmaceuticals, and AEs are current research hotspots. Machine learning is emerging research hotspots and trends in this field.
摘要：
各种生物疾病缓解抗风湿药（bDMARD）已被用于治疗轴向脊柱关节炎（axSpA）。然而,明显缺乏bDMARDs对axSpA的文献计量分析。2004年至2022年发表的与使用bDMARD治疗axSpA相关的文章来自WebofScience核心合集。VOS查看器1.6.18和CiteSpace6.1。R2用于分析和可视化出版物的数量和引用，以及确定该领域的“研究热点”和趋势。BibExcel版本1.0.0和gCLUTO版本1.0用于构建用于双聚类分析的矩阵。本文献计量分析共包括2546篇涉及用于治疗axSpA的bDMARD的文章。总的来说,出版物的数量每年稳步增加。美国（23.21%，591种出版物)以论文产量最高的排名第一，其次是德国，和荷兰。RheumazentrumRuhrgebiet排名第一，是最频繁的出版商（119篇文章）。风湿病年鉴发表的文献最多(6.76%，172种出版物)。主要的热点是结核病，\“\”IL-17，\”和\“生活质量\”，直到2020年。自2015年以来，“生物仿制药”一直保持着流行。目前的研究热点是“脊柱影像学进展，“Janus激酶（JAK）抑制剂，和不良事件（AE）。机器学习已经逐渐普及。全球范围内,关于bDMARDs用于axSpA的研究数量稳步增加。JAK抑制剂,脊柱影像学进展，生物仿制药，和AE是当前的研究热点。机器学习是该领域的新兴研究热点和趋势。
